Evidence map›Paper›PMID 34713149›Full record

ArticleFrontiers in digital health2021

Toward a Common Performance and Effectiveness Terminology for Digital Proximity Tracing Applications.

Wouter Lueks, Justus Benzler, Dan Bogdanov, Göran Kirchner, Raquel Lucas, Rui Oliveira, Bart Preneel, Marcel Salathé, Carmela Troncoso, Viktor von Wyl

Abstract read
In one paragraph

Article in Frontiers in digital health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. COVID-19 contact tracing in Belgium: main indicators and performance, January - September 2021.Archives of public health = Archives belges de sante publique · 2022
    Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Wouter LueksSecurity and Privacy Engineering Laboratory, School of Computer and Communication Sciences, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
Justus BenzlerRobert Koch Institute, Berlin, Germany.
Dan BogdanovCybernetica AS, Tartu, Estonia.
Göran KirchnerRobert Koch Institute, Berlin, Germany.
Raquel LucasMedical School and Institute of Public Health (EPIUnit), Universidade Do Porto, Porto, Portugal.
Rui OliveiraInstitute for Systems and Computer Engineering, Technology and Science & University of Minho, Porto, Portugal.
Bart PreneelDepartment of Electrical Engineering, Katholieke Universiteit Leuven and IMEC, Leuven, Belgium.
Marcel SalathéDigital Epidemiology Laboratory, School of Life Sciences, School of Computer and Communication Sciences, École Polytechnique Fédérale de Lausanne, Global Health Institute, Geneva, Switzerland.
Carmela TroncosoSecurity and Privacy Engineering Laboratory, School of Computer and Communication Sciences, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
Viktor von WylDigital and Mobile Health Group, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Digital proximity tracing (DPT) for Sars-CoV-2 pandemic mitigation is a complex intervention with the primary goal to notify app users about possible risk exposures to infected persons. DPT not only relies on the technical functioning of the proximity tracing application and its backend server, but also on seamless integration of health system processes such as laboratory testing, communication of results (and their validation), generation of notification codes, manual contact tracing, and management of app-notified users. Policymakers and DPT operators need to know whether their system works as expected in terms of speed or yield (performance) and whether DPT is making an effective contribution to pandemic mitigation (also in comparison to and beyond established mitigation measures, particularly manual contact tracing). Thereby, performance and effectiveness are not to be confused. Not only are there conceptual differences but also diverse data requirements. For example, comparative effectiveness measures may require information generated outside the DPT system, e.g., from manual contact tracing. This article describes differences between performance and effectiveness measures and attempts to develop a terminology and classification system for DPT evaluation. We discuss key aspects for critical assessments of whether the integration of additional data measurements into DPT apps may facilitate understanding of performance and effectiveness of planned and deployed DPT apps. Therefore, the terminology and a classification system may offer some guidance to DPT system operators regarding which measurements to prioritize. DPT developers and operators may also make conscious decisions to integrate measures for epidemic monitoring but should be aware that this introduces a secondary purpose to DPT. Ultimately, the integration of further information (e.g., regarding exact exposure time) into DPT involves a trade-off between data granularity and linkage on the one hand, and privacy on the other. More data may lead to better epidemiological information but may also increase the privacy risks associated with the system, and thus decrease public DPT acceptance. Decision-makers should be aware of the trade-off and take it into account when planning and developing DPT systems or intending to assess the added value of DPT relative to the existing contact tracing systems.

Indexed as

contact tracing appcoronavirusCOVID-19digital healthdigital proximity tracingeffectivenessperformance

Identifiers

PMID34713149
PMCPMC8521913

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.